MannKind Corporation Providing AFREZZA to Juvenile Diabetes Research Foundation for Artificial Pancreas Project

Mon, 08/23/2010 - 5:09am

MannKind Corporation today announced that the company will supply its novel, ultra rapid acting insulin AFREZZATM (insulin human rDNA origin) for use in a study being conducted by the Juvenile Diabetes Research Foundation (JDRF) as part of its Artificial Pancreas Project. The planned two-year study in patients with type 1 diabetes will leverage the unique rapid action of AFREZZA for use in a closed-loop blood sugar monitoring and insulin delivery system, termed the "artificial pancreas" by the JDRF. The study will be managed in conjunction with the Sansum Diabetes Research Institute and the University of California, Santa Barbara.

The JDRF is the leader in research leading to a cure for type 1 diabetes in the world. The JDRF's Artificial Pancreas Project is a partnership that brings together diabetes researchers and business focused on making the artificial pancreas a reality. The goal of the Project is to speed the development of automated diabetes management systems.

"MannKind is pleased to provide our investigational therapy AFREZZA to the Juvenile Diabetes Research Foundation for this important initiative," said Dr. Peter Richardson, MRCP, Corporate Vice President and Chief Scientific Officer of MannKind Corporation. "We support and share the goals of the Foundation to advance diabetes research, address poorly met needs in diabetes therapy, and help the people with this challenging disease achieve better outcomes." AFREZZA is a novel, ultra rapid acting mealtime insulin therapy with an action profile that mimics meal-related early insulin release, and is conveniently administered by oral inhalation.

"We are grateful for MannKind's contribution to this exciting JDRF research, and the opportunity to use AFREZZA in our study at Sansum, because AFREZZA has a pharmacokinetic profile that is similar to the body's natural insulin release," said Howard Zisser, MD, Director of Clinical Research and Diabetes Technology, Sansum Diabetes Research Institute, and Adjunct Professor, Department of Chemical Engineering, University of California, Santa Barbara. "This PK profile has not been achieved by any of the insulins used in artificial pancreas projects or by existing insulin pumps." Researchers at UC Santa Barbara have developed a uniquely flexible Artificial Pancreas System platform that enables investigators to use a variety of blood glucose sensors and insulin delivery devices in their research.

"This is the only system that allows fully automated closed-loop clinical trials, and its design allows it to be expanded as new devices and drugs become available," said Dr. Eyal Dassau, lead scientist for UC Santa Barbara's Artificial Pancreas System. "The use of AFREZZA in conjunction with the UCSB / Sansum Artificial Pancreas System will help in blunting the meal response and improving glycemic control."  



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.